Mannose ameliorates experimental colitis by protecting intestinal barrier integrity

Lijun Dong, Jingwen Xie, Youyi Wang, Honglian Jiang, Kai Chen, Dantong Li, Jing Wang, Yunzhi Liu, Jia He, Jia Zhou, Liyun Zhang, Xiao Lu, Xiaoming Zou, Xiang-Yang Wang, Qingqing Wang (), Zhengliang Chen () and Daming Zuo ()
Additional contact information
Lijun Dong: Southern Medical University
Jingwen Xie: Southern Medical University
Youyi Wang: Southern Medical University
Honglian Jiang: Southern Medical University
Kai Chen: Southern Medical University
Dantong Li: Southern Medical University
Jing Wang: Southern Medical University
Yunzhi Liu: Southern Medical University
Jia He: Zhejiang University School of Medicine
Jia Zhou: Southern Medical University
Liyun Zhang: Southern Medical University
Xiao Lu: Southern Medical University
Xiaoming Zou: Southern Medical University
Xiang-Yang Wang: Virginia Commonwealth University
Qingqing Wang: Zhejiang University School of Medicine
Zhengliang Chen: Southern Medical University
Daming Zuo: Southern Medical University

Nature Communications, 2022, vol. 13, issue 1, 1-17

Abstract: Abstract Metabolite alteration has been associated with the pathogenesis of inflammatory bowel disease (IBD), including colitis. Mannose, a natural bioactive monosaccharide that is involved in metabolism and synthesis of glycoproteins, exhibits anti-inflammatory and anti-oxidative activities. We show here that the circulating level of mannose is increased in patients with IBD and mice with experimental colitis. Mannose treatment attenuates intestinal barrier damage in two mouse colitis models, dextran sodium sulfate (DSS)-induced colitis and spontaneous colitis in IL-10-deficient mice. We demonstrate that mannose treatment enhanced lysosomal integrity and limited the release of cathepsin B, preventing mitochondrial dysfunction and myosin light chain kinase (MLCK)-induced tight junction disruption in the context of intestinal epithelial damage. Mannose exerts a synergistic therapeutic effect with mesalamine on mouse colitis. Cumulatively, the results indicate that mannose supplementation may be an optional approach to the treatment of colitis and other diseases associated with intestinal barrier dysfunction.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32505-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32505-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32505-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().